VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q43008303 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241020233026.0
008 241020nneanz||abbn n and d
035 ‎‡a (WKP)Q43008303‏
024 ‎‡a 0000-0002-6993-2450‏ ‎‡2 orcid‏
024 ‎‡a 15845705200‏ ‎‡2 scopus‏
035 ‎‡a (OCoLC)Q43008303‏
100 0 ‎‡a Maria Gomes da Silva‏ ‎‡9 ast‏ ‎‡9 es‏ ‎‡9 sl‏
375 ‎‡a 2‏ ‎‡2 iso5218‏
400 0 ‎‡a Maria Gomes da Silva‏ ‎‡c researcher‏ ‎‡9 en‏
400 0 ‎‡a Maria Gomes da Silva‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
670 ‎‡a Author's A tumor volume and performance status model to predict outcome prior to treatment in diffuse large B-cell lymphoma‏
670 ‎‡a Author's COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey‏
670 ‎‡a Author's Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.‏
670 ‎‡a Author's Identification of a panel of ten cell surface protein antigens associated with immunotargeting of leukemias and lymphomas by peripheral blood gammadelta T cells‏
670 ‎‡a Author's Long-term survival in multiple myeloma‏
670 ‎‡a Author's Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association‏
670 ‎‡a Author's Monocarboxylate transporter 1 (MCT1), a tool to stratify acute myeloid leukemia (AML) patients and a vehicle to kill cancer cells‏
670 ‎‡a Author's Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies‏
670 ‎‡a Author's Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.‏
670 ‎‡a Author's Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study.‏
670 ‎‡a Author's Therapeutic options in relapsed or refractory peripheral T-cell lymphoma‏
670 ‎‡a Author's Three-way translocation‏
670 ‎‡a Author's Three-way translocation involves MLL, MLLT3, and a novel cell cycle control gene, FLJ10374, in the pathogenesis of acute myeloid leukemia with t(9;11;19)(p22;q23;p13.3).‏
670 ‎‡a Author's Three-way translocation (X;20;16)(p11;q13;q23) in essential thrombocythemia implicates NFATC2 in dysregulation of CSF2 expression and megakaryocyte proliferation.‏
670 ‎‡a Author's Treatment with Low Doses of Polyclonal Immunoglobulin Improves B Cell Function During Immune Reconstitution in a Murine Model‏
670 ‎‡a Author's Treatment with polyclonal immunoglobulin during T-cell reconstitution promotes naive T-cell proliferation.‏
909 ‎‡a (orcid) 0000000269932450‏ ‎‡9 1‏
909 ‎‡a (scopus) 15845705200‏ ‎‡9 1‏
919 ‎‡a longtermsurvivalinmultiplemyeloma‏ ‎‡A Long-term survival in multiple myeloma‏ ‎‡9 1‏
919 ‎‡a mediastinalgrayzonelymphomaclinicopathologicalcharacteristicsandoutcomesof99patientsfromthelymphomastudyassociation‏ ‎‡A Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association‏ ‎‡9 1‏
919 ‎‡a monocarboxylatetransporter1mct1atooltostratifyacutemyeloidleukemiaamlpatientsandavehicletokillcancercells‏ ‎‡A Monocarboxylate transporter 1 (MCT1), a tool to stratify acute myeloid leukemia (AML) patients and a vehicle to kill cancer cells‏ ‎‡9 1‏
919 ‎‡a poorconcordanceamong9immunohistochemistryclassifiersofcelloforiginfordiffuselargebcelllymphomaimplicationsfortherapeuticstrategies‏ ‎‡A Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies‏ ‎‡9 1‏
919 ‎‡a riskfactorsandoutcomesforpatientswithfollicularlymphomawhohadhistologictransformationafterresponseto1lineimmunochemotherapyintheprimatrial‏ ‎‡A Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.‏ ‎‡9 1‏
919 ‎‡a statinuseissafeanddoesnotimpactprognosisinpatientwithdenovofollicularlymphomatreatedwithimmunochemotherapyanexploratoryanalysisoftheprimacohortstudy‏ ‎‡A Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study.‏ ‎‡9 1‏
919 ‎‡a 3waytranslocation‏ ‎‡A Three-way translocation‏ ‎‡9 1‏
919 ‎‡a 3waytranslocationinvolvesmllmllt3andanovelcellcyclecontrolgeneflj10374inthepathogenesisofacutemyeloidleukemiawitht91119p22q23p133‏ ‎‡A Three-way translocation involves MLL, MLLT3, and a novel cell cycle control gene, FLJ10374, in the pathogenesis of acute myeloid leukemia with t(9;11;19)(p22;q23;p13.3).‏ ‎‡9 1‏
919 ‎‡a 3waytranslocation102016p11q13q23inessentialthrombocythemiaimplicatesnfatc2indysregulationofcsf2expressionandmegakaryocyteproliferation‏ ‎‡A Three-way translocation (X;20;16)(p11;q13;q23) in essential thrombocythemia implicates NFATC2 in dysregulation of CSF2 expression and megakaryocyte proliferation.‏ ‎‡9 1‏
919 ‎‡a treatmentwithlowdosesofpolyclonalimmunoglobulinimprovesbcellfunctionduringimmunereconstitutioninamurinemodel‏ ‎‡A Treatment with Low Doses of Polyclonal Immunoglobulin Improves B Cell Function During Immune Reconstitution in a Murine Model‏ ‎‡9 1‏
919 ‎‡a treatmentwithpolyclonalimmunoglobulinduringtcellreconstitutionpromotesnaivetcellproliferation‏ ‎‡A Treatment with polyclonal immunoglobulin during T-cell reconstitution promotes naive T-cell proliferation.‏ ‎‡9 1‏
919 ‎‡a therapeuticoptionsinrelapsedorrefractoryperipheraltcelllymphoma‏ ‎‡A Therapeutic options in relapsed or refractory peripheral T-cell lymphoma‏ ‎‡9 1‏
919 ‎‡a tumorvolumeandperformancestatusmodeltopredictoutcomepriortotreatmentindiffuselargebcelllymphoma‏ ‎‡A A tumor volume and performance status model to predict outcome prior to treatment in diffuse large B-cell lymphoma‏ ‎‡9 1‏
919 ‎‡a covid19andhairycellleukemiaanepicovidehasurvey‏ ‎‡A COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey‏ ‎‡9 1‏
919 ‎‡a diffuselargebcelllymphomadlbclesmoclinicalpracticeguidelinesfordiagnosistreatmentandfollowup‏ ‎‡A Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.‏ ‎‡9 1‏
919 ‎‡a identificationofapanelof10cellsurfaceproteinantigensassociatedwithimmunotargetingofleukemiasandlymphomasbyperipheralbloodgammadeltatcells‏ ‎‡A Identification of a panel of ten cell surface protein antigens associated with immunotargeting of leukemias and lymphomas by peripheral blood gammadelta T cells‏ ‎‡9 1‏
946 ‎‡a a‏ ‎‡9 1‏
996 ‎‡2 ISNI|000000006961487X‏
996 ‎‡2 LC|ns2012004211‏
996 ‎‡2 BLBNB|001579020‏
996 ‎‡2 DNB|1157148115‏
996 ‎‡2 DNB|1029702330‏
996 ‎‡2 ISNI|0000000457384359‏
996 ‎‡2 ISNI|0000000051503354‏
996 ‎‡2 ISNI|0000000373154791‏
996 ‎‡2 NII|DA11481170‏
996 ‎‡2 BNF|16224220‏
996 ‎‡2 BNCHL|10000000000000000281971‏
996 ‎‡2 PTBNP|166300‏
996 ‎‡2 PTBNP|30336‏
996 ‎‡2 ISNI|0000000070236474‏
996 ‎‡2 BNE|XX867974‏
996 ‎‡2 BLBNB|000471820‏
996 ‎‡2 PTBNP|1771833‏
996 ‎‡2 ISNI|0000000069191387‏
996 ‎‡2 BLBNB|000318802‏
996 ‎‡2 SUDOC|245092943‏
996 ‎‡2 BLBNB|000477322‏
996 ‎‡2 ISNI|0000000036447470‏
996 ‎‡2 ISNI|0000000459749147‏
996 ‎‡2 LC|n 89104244‏
996 ‎‡2 DNB|1158098626‏
996 ‎‡2 PLWABN|9812628193905606‏
996 ‎‡2 RERO|A003831994‏
996 ‎‡2 ISNI|0000000385524446‏
996 ‎‡2 SUDOC|181140810‏
996 ‎‡2 DNB|1049573080‏
996 ‎‡2 LC|n 2012210984‏
996 ‎‡2 LC|no2020120011‏
996 ‎‡2 JPG|500372352‏
996 ‎‡2 PTBNP|179260‏
996 ‎‡2 PTBNP|1492112‏
996 ‎‡2 LC|n 2019252362‏
996 ‎‡2 ISNI|0000000031166936‏
996 ‎‡2 BLBNB|000552182‏
996 ‎‡2 ISNI|0000000066472204‏
996 ‎‡2 ISNI|0000000110625416‏
996 ‎‡2 PTBNP|1205040‏
996 ‎‡2 LC|no2004013669‏
996 ‎‡2 PTBNP|1890409‏
996 ‎‡2 ISNI|0000000069386600‏
996 ‎‡2 PTBNP|1572668‏
996 ‎‡2 RERO|A025264592‏
996 ‎‡2 DNB|1113614420‏
996 ‎‡2 PTBNP|1175749‏
996 ‎‡2 ISNI|0000000069699252‏
996 ‎‡2 BIBSYS|14040026‏
996 ‎‡2 ISNI|000000006382346X‏
996 ‎‡2 BLBNB|000536971‏
996 ‎‡2 SUDOC|117234893‏
996 ‎‡2 PTBNP|997759‏
996 ‎‡2 ISNI|0000000070108608‏
996 ‎‡2 BLBNB|000532405‏
996 ‎‡2 SUDOC|085817708‏
996 ‎‡2 BLBNB|001115503‏
996 ‎‡2 BLBNB|001011252‏
996 ‎‡2 RERO|A000062629‏
996 ‎‡2 NUKAT|n 2008049743‏
996 ‎‡2 ISNI|0000000503858501‏
996 ‎‡2 LC|no2020003454‏
996 ‎‡2 PTBNP|127316‏
996 ‎‡2 PTBNP|1239161‏
996 ‎‡2 LC|no2020148359‏
996 ‎‡2 ISNI|0000000070026346‏
996 ‎‡2 DNB|1056281308‏
996 ‎‡2 SUDOC|07478644X‏
996 ‎‡2 BLBNB|000294473‏
996 ‎‡2 LC|n 88139951‏
996 ‎‡2 LC|n 2022250561‏
996 ‎‡2 PTBNP|73173‏
996 ‎‡2 NUKAT|nx2023952209‏
996 ‎‡2 PTBNP|1446050‏
996 ‎‡2 BLBNB|000180483‏
996 ‎‡2 ISNI|0000000069220897‏
996 ‎‡2 PTBNP|949127‏
996 ‎‡2 ISNI|0000000069182835‏
996 ‎‡2 PTBNP|1266875‏
996 ‎‡2 BIBSYS|90347819‏
996 ‎‡2 SUDOC|159472946‏
996 ‎‡2 BNCHL|10000000000000000045162‏
996 ‎‡2 ISNI|0000000068515634‏
996 ‎‡2 ISNI|0000000031930084‏
996 ‎‡2 LC|no2018006392‏
996 ‎‡2 PTBNP|1902672‏
996 ‎‡2 BLBNB|001585886‏
996 ‎‡2 BAV|495_38811‏
996 ‎‡2 PTBNP|1429971‏
996 ‎‡2 ISNI|000000007321676X‏
996 ‎‡2 BNF|13746840‏
996 ‎‡2 RERO|A000172631‏
996 ‎‡2 LC|no2006028927‏
996 ‎‡2 PTBNP|1339266‏
996 ‎‡2 BLBNB|000558937‏
996 ‎‡2 SUDOC|146711769‏
996 ‎‡2 ISNI|0000000070732726‏
996 ‎‡2 BLBNB|001467489‏
996 ‎‡2 LC|n 91062633‏
996 ‎‡2 ISNI|0000000070093928‏
996 ‎‡2 BLBNB|000480540‏
996 ‎‡2 NUKAT|n 2012275445‏
996 ‎‡2 SUDOC|176882138‏
996 ‎‡2 BLBNB|000221169‏
996 ‎‡2 BIBSYS|3018843‏
996 ‎‡2 DNB|1077679769‏
996 ‎‡2 SUDOC|03257813X‏
996 ‎‡2 ISNI|0000000070326453‏
996 ‎‡2 ISNI|0000000047913852‏
996 ‎‡2 PTBNP|48132‏
996 ‎‡2 LC|no2016151226‏
996 ‎‡2 PTBNP|968939‏
996 ‎‡2 ISNI|0000000500909078‏
996 ‎‡2 LC|n 99901045‏
996 ‎‡2 LC|n 95036735‏
996 ‎‡2 BLBNB|000235948‏
996 ‎‡2 ISNI|0000000069413103‏
996 ‎‡2 ISNI|0000000120380723‏
996 ‎‡2 LC|no2019172519‏
996 ‎‡2 NYNYRILM|390826‏
996 ‎‡2 ISNI|0000000068215316‏
996 ‎‡2 DNB|139818707‏
996 ‎‡2 NUKAT|n 98037282‏
996 ‎‡2 LC|n 2018252036‏
996 ‎‡2 PTBNP|1215539‏
996 ‎‡2 ISNI|0000000068489763‏
996 ‎‡2 RERO|A009594918‏
996 ‎‡2 LC|n 2006218979‏
996 ‎‡2 BLBNB|000221612‏
996 ‎‡2 CAOONL|ncf11246621‏
996 ‎‡2 PTBNP|1816389‏
996 ‎‡2 BLBNB|000169246‏
996 ‎‡2 LC|n 90617632‏
996 ‎‡2 LC|no2002060129‏
996 ‎‡2 PTBNP|218622‏
996 ‎‡2 PTBNP|797523‏
996 ‎‡2 SUDOC|139514929‏
996 ‎‡2 J9U|987007432115605171‏
996 ‎‡2 PTBNP|257646‏
996 ‎‡2 BLBNB|001431757‏
996 ‎‡2 PTBNP|1362644‏
996 ‎‡2 ISNI|000000006764467X‏
996 ‎‡2 LC|no2003050083‏
996 ‎‡2 BLBNB|000181465‏
996 ‎‡2 BLBNB|000434071‏
996 ‎‡2 BLBNB|000354175‏
996 ‎‡2 BLBNB|000354172‏
996 ‎‡2 RERO|A024996098‏
996 ‎‡2 LC|n 2023180701‏
996 ‎‡2 DNB|1056667583‏
996 ‎‡2 PTBNP|1261369‏
996 ‎‡2 ISNI|0000000359924120‏
996 ‎‡2 ISNI|0000000067685674‏
996 ‎‡2 BNC|981058518320306706‏
996 ‎‡2 BLBNB|001537543‏
996 ‎‡2 PTBNP|1369016‏
996 ‎‡2 LC|n 95018695‏
996 ‎‡2 BLBNB|000344432‏
996 ‎‡2 BLBNB|000630165‏
996 ‎‡2 BLBNB|001466425‏
996 ‎‡2 LC|no2019063580‏
996 ‎‡2 LC|no2002017749‏
996 ‎‡2 PTBNP|240381‏
996 ‎‡2 ISNI|000000049981859X‏
996 ‎‡2 PTBNP|123943‏
996 ‎‡2 BLBNB|000188767‏
996 ‎‡2 PTBNP|1701114‏
996 ‎‡2 SUDOC|137034741‏
996 ‎‡2 BLBNB|000458220‏
996 ‎‡2 ISNI|0000000068301070‏
996 ‎‡2 BLBNB|001114350‏
996 ‎‡2 BAV|495_46116‏
996 ‎‡2 PTBNP|1513597‏
996 ‎‡2 BLBNB|000354372‏
996 ‎‡2 PTBNP|67491‏
996 ‎‡2 BLBNB|000470206‏
996 ‎‡2 ISNI|0000000099661191‏
996 ‎‡2 PTBNP|1633337‏
996 ‎‡2 PTBNP|89999‏
996 ‎‡2 LC|n 88012121‏
996 ‎‡2 BNE|XX5457305‏
996 ‎‡2 ISNI|0000000071002303‏
996 ‎‡2 ISNI|0000000070337662‏
996 ‎‡2 ISNI|0000000070633701‏
996 ‎‡2 PTBNP|343062‏
996 ‎‡2 BLBNB|000240618‏
996 ‎‡2 BLBNB|000442962‏
996 ‎‡2 PTBNP|952849‏
996 ‎‡2 BLBNB|001430577‏
996 ‎‡2 ISNI|0000000036411590‏
996 ‎‡2 PTBNP|261630‏
996 ‎‡2 SUDOC|266105556‏
996 ‎‡2 BLBNB|000365128‏
996 ‎‡2 ISNI|0000000027196091‏
996 ‎‡2 ISNI|0000000081698527‏
996 ‎‡2 ISNI|0000000041775604‏
996 ‎‡2 ISNI|0000000068985935‏
996 ‎‡2 LC|n 2007206123‏
996 ‎‡2 BNF|17085968‏
996 ‎‡2 ISNI|0000000041338690‏
996 ‎‡2 BNF|17079063‏
996 ‎‡2 LC|no2015040453‏
996 ‎‡2 PTBNP|193936‏
996 ‎‡2 DNB|1056466189‏
996 ‎‡2 PTBNP|839104‏
996 ‎‡2 DNB|1074668952‏
996 ‎‡2 DNB|139914943‏
996 ‎‡2 ISNI|0000000066392802‏
996 ‎‡2 BLBNB|000219315‏
996 ‎‡2 SUDOC|26299805X‏
996 ‎‡2 ISNI|0000000069114402‏
996 ‎‡2 BNF|17828663‏
996 ‎‡2 SUDOC|09227188X‏
996 ‎‡2 NUKAT|n 2011110719‏
996 ‎‡2 ISNI|0000000098511722‏
996 ‎‡2 LC|n 85300179‏
996 ‎‡2 ISNI|0000000068598193‏
996 ‎‡2 ISNI|0000000070524839‏
996 ‎‡2 BLBNB|000354247‏
996 ‎‡2 PTBNP|991589‏
996 ‎‡2 PTBNP|273267‏
996 ‎‡2 ISNI|000000006798114X‏
996 ‎‡2 LC|no2012012514‏
996 ‎‡2 BLBNB|001127841‏
996 ‎‡2 SUDOC|277400511‏
996 ‎‡2 DNB|1074669770‏
996 ‎‡2 DNB|1122703899‏
996 ‎‡2 NUKAT|n 2015178353‏
996 ‎‡2 SUDOC|11002897X‏
996 ‎‡2 SUDOC|085779806‏
996 ‎‡2 DNB|120417184X‏
996 ‎‡2 BLBNB|000482762‏
996 ‎‡2 PTBNP|1822920‏
996 ‎‡2 NKC|jo20221159218‏
996 ‎‡2 SUDOC|077513592‏
996 ‎‡2 BLBNB|000399220‏
996 ‎‡2 BIBSYS|4104713‏
996 ‎‡2 DNB|1139149407‏
996 ‎‡2 LC|no 97005668‏
996 ‎‡2 BLBNB|001474257‏
996 ‎‡2 BLBNB|001475388‏
996 ‎‡2 ISNI|0000000070998081‏
996 ‎‡2 DNB|1159175888‏
996 ‎‡2 ISNI|0000000081693742‏
996 ‎‡2 ISNI|0000000070523940‏
996 ‎‡2 BNE|XX1505689‏
996 ‎‡2 DNB|1219178640‏
996 ‎‡2 ISNI|0000000069225604‏
996 ‎‡2 PTBNP|204683‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏